Mersana Therapeutics (MRSN) Competitors $0.34 +0.01 (+4.26%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. LXEO, BIVI, BIOA, VTYX, MOLN, IMRX, THTX, NMRA, ALEC, and LYELShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Lexeo Therapeutics (LXEO), BioVie (BIVI), BioAge Labs (BIOA), Ventyx Biosciences (VTYX), Molecular Partners (MOLN), Immuneering (IMRX), Theratechnologies (THTX), Neumora Therapeutics (NMRA), Alector (ALEC), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Its Competitors Lexeo Therapeutics BioVie BioAge Labs Ventyx Biosciences Molecular Partners Immuneering Theratechnologies Neumora Therapeutics Alector Lyell Immunopharma Mersana Therapeutics (NASDAQ:MRSN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Does the media favor MRSN or LXEO? In the previous week, Lexeo Therapeutics had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 1 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.87 beat Lexeo Therapeutics' score of 0.45 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Very Positive Lexeo Therapeutics Neutral Do analysts recommend MRSN or LXEO? Mersana Therapeutics currently has a consensus target price of $5.20, indicating a potential upside of 1,429.41%. Lexeo Therapeutics has a consensus target price of $16.60, indicating a potential upside of 295.71%. Given Mersana Therapeutics' higher probable upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in MRSN or LXEO? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, MRSN or LXEO? Mersana Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Is MRSN or LXEO more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Lexeo Therapeutics' return on equity of -85.86% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-217.63% -990.16% -48.87% Lexeo Therapeutics N/A -85.86%-68.48% Which has higher valuation and earnings, MRSN or LXEO? Mersana Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$34.01M1.25-$69.19M-$0.59-0.58Lexeo TherapeuticsN/AN/A-$98.33M-$3.30-1.27 SummaryMersana Therapeutics beats Lexeo Therapeutics on 10 of the 14 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.38M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.5820.3528.6119.64Price / Sales1.25304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book-4.257.718.185.63Net Income-$69.19M-$55.11M$3.23B$257.73M7 Day Performance0.83%0.68%-0.25%0.07%1 Month Performance-10.50%8.22%5.40%8.32%1 Year Performance-84.89%-2.64%26.35%13.78% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.1572 of 5 stars$0.34+4.3%$5.20+1,429.4%-84.3%$42.38M$34.01M-0.58150Positive NewsLXEOLexeo Therapeutics2.0196 of 5 stars$4.54+2.0%$16.60+265.6%-68.3%$150.73M$650K-1.3858Gap UpHigh Trading VolumeBIVIBioVie1.0544 of 5 stars$8.10-15.6%N/A+60.3%$150.42MN/A-1.0210Positive NewsGap UpBIOABioAge LabsN/A$4.18-2.3%N/AN/A$149.85MN/A0.00N/AVTYXVentyx Biosciences3.4706 of 5 stars$2.04-1.9%$10.00+390.2%+6.7%$148.02MN/A-1.1730Positive NewsMOLNMolecular Partners3.0736 of 5 stars$3.61-4.0%$12.00+232.4%-43.5%$145.77M$5.65M-1.88180Positive NewsGap DownIMRXImmuneering3.2597 of 5 stars$4.05+17.4%$13.25+227.2%+242.6%$145.76M$320K-2.0760THTXTheratechnologiesN/A$3.17-0.9%N/A+103.9%$145.76M$85.87M-39.63140Earnings ReportHigh Trading VolumeNMRANeumora Therapeutics2.7245 of 5 stars$0.90+9.0%$9.29+937.2%-87.5%$144.81MN/A-0.56108News CoveragePositive NewsAnalyst ForecastGap UpALECAlector3.8285 of 5 stars$1.44-4.6%$4.00+177.8%-72.9%$143.99M$100.56M-1.14270Gap UpLYELLyell Immunopharma3.2463 of 5 stars$9.15-5.6%$15.00+63.9%-73.5%$143.49M$65K-0.37270News Coverage Related Companies and Tools Related Companies LXEO Competitors BIVI Competitors BIOA Competitors VTYX Competitors MOLN Competitors IMRX Competitors THTX Competitors NMRA Competitors ALEC Competitors LYEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
